WEE1 seems to be an attractive target in medulloblastoma (MB): a systematic literature review by Keller et al. (2022)23 found that inhibitors of WEE1 and other cell cycle kinases are the most promising therapeutics in MB as single agents as well as in combination with chemotherapy and radiotherapy (RT). This evidence concerns the gene WEE1 and medulloblastoma.